Velvio develops new medicines to restore organ repair functions for treatment in Neurodegeneration and Pulmonary Fibrosis, first in Orphan diseases Amyotrophic Lateral Sclerosis (ALS) and Idiopathic pulmonary Fibrosis (IPF). Furthermore, Velvio targets to enhance clinical responses of solid tumors to Immune-Oncology treatment concepts. Based on our highly promising pre-clinical pipeline, we are ready to go “first in man” in ALS, in IPF we are about to finish preclinical in vivo drug development.

Our company profile 

Our mission

Revert Inflammation - Restore Repair - Regain Health


Ageing and chronic disease have upregulated TGF-β:

  • Neurodegeneration
  • Fibrotic Disorders
  • Tumors

Hitting single targets of complex disorders leads to incomplete success

Chronically elevated TGF-β signaling arrests repair. Stops: stem cells. Starts: fibrosis - scarring, destructive immune dysfunction.


NVP-13 – a new LNAGapmer
Antisense drug downregulates TGF-β signaling.

NVP-13 has broad effects on competitive downstream targets, simultaneously.

Chronic inflammation, fibrosis and toxic tissue milieu as primary targets.

Re-enable active regeneration by stem cells and restore organ repair and function.

Next Steps

Initial studies in Neurodegeneration (ALS) and Idiopathic Pulmonary Fibrosis (IPF)

Pipeline Development in Immune-Oncology for increased response rates with various compounds

Pipeline Development in Liver Disease

Velvio GmbH

Am Biopark 11
93053 Regensburg | Germany

+49 (0) 941 463 747-37